An Era Concludes: CureVac’s Stock Market Journey Ends Following BioNTech Acquisition
27.01.2026 - 16:24:04
The independent public listing of Tübingen-based mRNA pioneer CureVac has been formally terminated. The company’s shares have been delisted from exchanges, marking the final chapter in its standalone history, after competitor BioNTech completed a full acquisition. For former shareholders, a critical deadline is now imminent: the final opportunity to reclaim Dutch withholding tax expires today, January 27, 2026.
BioNTech’s takeover was formally concluded on January 6, 2026, following a completed restructuring. This move granted BioNTech sole ownership of all business operations. The former CureVac SE entity was replaced by its legal successor, CureVac Merger B.V., a step that finalized the delisting process.
Key transaction metrics highlight the scale of this Read more...
@ boerse-global.de | NL0015436031 ERA
